Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension

Diabetes, Obesity and Metabolism

Volumn 10, Issue 9, 2008, Pages 719-725

  Konduracka, Ewa ^a   Galicka Latala, D ^a   Cieslik, G ^b   Rostoff, P ^a   Fedak, D ^a   Sieradzki, J ^a   Naskalski, J ^a   Piwowarska, W ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Centre for Treatment of Civilization Induced Diseases   (Poland)

Author keywords

Cardiovascular disease; Endothelium; Prevention; Type 1 diabetes mellitus

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE DURATION; DISEASE MARKER; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; FATIGUE; FEMALE; FLATULENCE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 50249145187     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00798.x     Document Type: Article

References (39)

1. Chlopicki S, Gryglewski RJ. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep 2005; 57: 86-96.
2. Blann AD. Assessment of endothelial dysfunction: Focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2003-2004; 33: 256-261.
3. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 2001; 22: 36-52.
4. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci 2005; 109: 143-159.
5. Chaturvedi N, Sjoelie AK, Porta M et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001; 24: 284-289.
6. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomized controlled trials. BMJ 2006; 332: 1115-1124.
7. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5: 81-87.
8. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
9. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-288.
10. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-1164.
11. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee On Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
12. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
13. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149: 473.
14. Mason RP, Walter MF, Jacob RF. Effect of HMG-CoA reductase inhibitors on endothelial function. Role of microdomains and oxidative stress. Circulation 2004; 109: II34-II41.
15. Spieker LE, Luscher TF. Protection of endothelial function. Handb Exp Pharmacol 2005; 170: 619-644.
16. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 2006; 6: 115-120.
17. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment - could it be pleiotropic effects? Am J Cardiol 2005; 96: 54F-60F.
18. Spijkerman AN, Dekker JM, Nijpels G et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: The Hoorn Study. Eur J Clin Invest 2002; 32: 924-930.
19. Gaede P, Vedel P, Parving HH, Pedersen O. Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant 2001; 16: 2028-2033.
20. Joughadar C, Klein N, Prinz M et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85: 47-51.
21. Van der Ree MA, de Maat MPM, Kluft C et al. Decrease of cardiovascular risk factors by aggressive v conventional atorvastatin treatment in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 1753-1757.
22. Chan NN, Fuller JH, Rubens M, Colhoun HM. Von Willebrand factor in type 1 diabetes: Its production and coronary artery calcification. Med Sci Monit 2003; 9: 297-303.
23. Anderson R, Dart AM, Starr J, Shaw J, Chin-Dusting JP. Plasma C-reactive protein but not protein S, VCAM-1, von Willebrand factor or P-selectin, is associated with endothelium dysfunction in coronary artery disease. Atherosclerosis 2004; 176: 423-424.
24. Brown AA, Hu FB. Dietary modulation on endothelial function: Implication for cardiovascular disease. Am J Clin Nutr 2001; 73: 673-686.
25. Jae SY, Fernhall B, Heffernan KS et al. Effects of lifestyle modifications on C-reactive protein: Contribution of weight loss and improved aerobic capacity. Metabolism 2006; 55: 825-831.
26. Martin CM, Almond J. New frontiers for cardiac risk assessment: C-reactive protein. Consult Pharm 2006; 21: 188-191.
27. Ikonomidis I, Lekakis J, Kremastinos DT et al. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a 'multimarker' approach? Thromb Haemost 2006; 95: 397-398.
28. Fearnley GR, Chakrabarti R, Avis PR. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. Br Med J 1963; 1: 921-923.
29. Trifiletti A, Lasco A, Scamardi R et al. Long-term hemostatic effects of cholesterol- lowering therapy with atorvastatin. Pathophysiol Haemost Thromb 2003; 33: 84-87.
30. Ushiroyama T, Nosaka S, Ueki M. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. Int J Cardiol 2006; 113: 66-75.
31. Goicoechea M, de Vinuesa SG, Lahera V et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: S231-S235.
32. Orem C, Uydu H, Yilmaz R et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J 2004; 45: 977-987.
33. Davidson M, McKenney J, Stein E et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-1481.
34. Mitropoulos K, Armitage J, Collins R et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18: 235-241.
35. Ludwig S, Dharmalingam S, Erickson-Nesmith S et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 70: 110-118.
36. Wada H, Mori Y, Kaneko T et al. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin. Clin Ther 1992; 14: 829-834.
37. Isaacsohn J, Setaro J, Nicholas C et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74: 735-737.
38. Lee JD, Morrissey JR, Mikhailidis DP, Patel V. CARDS on the table: should everybody with type 2 diabetes take a statin? Curr Med Res Opin 2005; 21: 357-362.
39. Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 2000; 84: 357-360.